0001564590-22-006349.txt : 20220223 0001564590-22-006349.hdr.sgml : 20220223 20220223172224 ACCESSION NUMBER: 0001564590-22-006349 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220223 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220223 DATE AS OF CHANGE: 20220223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STAAR SURGICAL CO CENTRAL INDEX KEY: 0000718937 STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851] IRS NUMBER: 953797439 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-11634 FILM NUMBER: 22665100 BUSINESS ADDRESS: STREET 1: 1911 WALKER AVE CITY: MONROVIA STATE: CA ZIP: 91016 BUSINESS PHONE: 6263037902 MAIL ADDRESS: STREET 1: 1911 WALKER AVE CITY: MONROVIA STATE: CA ZIP: 91016 FORMER COMPANY: FORMER CONFORMED NAME: STAAR SURGICAL COMPANY DATE OF NAME CHANGE: 19920703 8-K 1 staa-8k_20220223.htm 8-K staa-8k_20220223.htm
false 0000718937 0000718937 2022-02-23 2022-02-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 23, 2022

 

 

STAAR Surgical Company

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

0-11634

95-3797439

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

25651 Atlantic Ocean Drive

Lake Forest, California

 

92630

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 626-303-7902

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

STAA

NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

 

On February 23, 2022, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter and full year ended December 31, 2021, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

 

 This information and the information contained in the press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report, and Exhibit 99.1 are not incorporated by reference into any filings of STAAR made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release of the Company dated February 23, 2022.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

STAAR Surgical Company 

 

February 23, 2022

By:

/s/ Caren Mason

 

 

Caren Mason

 

 

President and Chief Executive Officer

 

 EX-99.1 2 staa-ex991_6.htm EX-99.1 staa-ex991_6.htm

Exhibit 99.1

 

 

 

STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results

 

LAKE FOREST, CA, February 23, 2022 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021.

 

Fourth Quarter 2021 Overview

 

 

•

Net Sales of $59.0 Million Up 28% from the Prior Year Quarter

 

•

ICL Sales of $53.0 Million Up 33% from the Prior Year Quarter

 

•

ICL Units Up 36% from the Prior Year Quarter

 

•

Gross Margin at 76.3% vs. 74.6% in the Prior Year Quarter

 

•

Net Income of $0.10 per Share vs. Prior Year Quarter Net Income of $0.07 per Share

 

•

Cash and Cash Equivalents Ended the Quarter at $199.7 Million

 

Full Year 2021 Overview

 

 

•

Record Net Sales of $230.5 Million Up 41% from Prior Year

 

•

ICL Sales Up 51% and Units Up 48% from the Prior Year

 

•

Gross Margin at 77.5% of Sales from 72.4% of Sales in the Prior Year

 

•

Full Year Net Income of $0.50 per Share vs. Prior Year Net Income of $0.12 per Share

 

“Our fiscal 2021 results reflect record levels of sales, profit and growth achievement for STAAR, driven by continued accelerating demand for our implantable Collamer® lenses,” said Caren Mason, President and CEO of STAAR Surgical. “For the full year, fiscal 2021, total company Net sales growth, up 41% year over year, accelerated from fiscal 2020 and the pre-pandemic level of 2019 driven by global ICL unit growth up 48%, which was almost three times the growth of global refractive industry procedures.1 During the fourth quarter, sales in Europe and our U.S. manufacturing operations were impacted by Covid-related staffing and throughput challenges which are now lessening. Global demand for our ICL continues unabated through the first seven weeks of the first quarter of 2022, including record orders from surgeons in China. In the U.S., our submission of clinical data for STAAR’s EVO family of myopia lenses remains under customary interactive FDA review. For fiscal 2022, we plan to invest more heavily in consumer awareness building programs designed to drive growth. The STAAR team will also continue to engage the ophthalmic community through clinical validation, education and strategic cooperation. We reaffirm our previously provided outlook for Net sales of approximately $295 million for fiscal 2022, subject to no unforeseen incremental impact from Covid on our business, which would represent 28% growth year over year and another record year of commercial and financial progress for STAAR.”

 

 

 

 

1 Market Scope Refractive Surgery Report, January 2022. Industry refractive procedures up 17%.

 

 

 

Financial Overview – Q4 2021

Net sales were $59.0 million for the fourth quarter of 2021, up 28% compared to $46.0 million reported in the prior year quarter. The sales increase was driven by ICL sales and unit growth of 33% and 36%, respectively, as compared to the prior year period. Other Product Sales decreased 3% compared to the prior year quarter. ICL sales was 90% of total Net sales for the fourth quarter of 2021.

Gross profit margin for the fourth quarter of 2021 was 76.3% compared to the prior year period of 74.6%. Factors impacting gross margin in the fourth quarter of 2021, as compared to the prior year period, include a higher mix of ICL sales and geographic sales mix, partially offset by an increase in expenses related to manufacturing projects.

Operating expenses for the fourth quarter of 2021 were $37.6 million compared to the prior year quarter of $30.2 million. General and administrative expenses were $11.5 million compared to the prior year quarter of $9.5 million. The increase in general and administrative expenses was due to increased compensation-related expenses, facilities costs and outside services. Selling and marketing expenses were $17.1 million compared to the prior year quarter of $11.8 million. The increase in selling and marketing expenses is due to increased advertising and promotional expenses, compensation-related expenses and trade show and meeting expenses. Research and development expenses were $9.1 million compared to the prior year quarter of $9.0 million as lower U.S. EVO clinical trial expenses offset the increase in compensation-related expenses related to additional hires.

Net income for the fourth quarter of 2021 was $4.9 million or $0.10 per diluted share compared with net income of $3.3 million or $0.07 per diluted share for the prior year quarter. The year over year increase is attributable to higher gross profit and operating income partially offset by other expense, primarily changes in foreign currency transactions. Adjusted Net Income for the fourth quarter of 2021 was $9.5 million or $0.19 per diluted share compared to $6.8 million or $0.14 per diluted share for the prior year quarter. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.

Financial Overview – Full Year 2021

Net sales were $230.5 million for full year (“FY”) 2021, up 41% compared to $163.5 million reported in the prior year. The increase in Net sales was driven by ICL sales and unit growth of 51% and 48%, respectively. Other Products Sales decreased 20% compared to the prior year due to lower sales of injectors and injector parts and IOLs. ICL sales were 92% of total Net sales for FY 2021 as compared to 87% for FY 2020.

Gross profit margin for FY 2021 increased to 77.5% of total net sales compared to 72.4% of total net sales for FY 2020. The increase in gross margin for the year is due to a higher mix of ICL sales, geographic sales mix, a decreased mix of injector part sales which carry a lower margin offset by increased period costs associated with the manufacturing expansion projects. FY 2020 gross margin was impacted by a voluntary pause in manufacturing at the Company’s principal manufacturing facility due to the pandemic.

Operating expenses for FY 2021 were $145.3 million compared to prior year of $111.6 million. The 30% increase in operating expense is primarily due to increased compensation-related expenses, marketing, promotion and advertising costs. Increases in meetings and trade show expenses, outside services and facilities costs were partially offset by a decrease in clinical expenses associated with the Company’s EVO clinical trial in the U.S.

Net income for FY 2021 was $24.5 million or approximately $0.50 per diluted share compared with net income of $5.9 million or $0.12 per diluted share for the prior year. The year over year increase in net income is due to higher gross profit and operating income offset partially offset by other expense, primarily changes in foreign currency transactions. Adjusted Net Income for FY 2021 was $42.9 million or $0.87 per diluted share, compared with an

2

 

 

 

Adjusted Net Income of $16.7 million or $0.35 per diluted share for FY 2020. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.

Cash and cash equivalents at December 31, 2021 totaled $199.7 million, compared to $152.5 million at end of the fourth quarter of 2020. The Company generated $44.0 million in cash from operations for FY 2021.

Conference Call

 

The Company will host a conference call and webcast today, Wednesday, February 23 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 142350), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

 

A taped replay of the conference call (Replay Code 610748) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 866-813-9403 for domestic callers and 929-458-6194 for international callers. An archived webcast will also be available at www.staar.com.

 

Use of Non-GAAP Financial Measures

This press release includes supplemental non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. “Adjusted Net Income” excludes the following items that are included in “Net Income” as calculated in accordance with U.S. generally accepted accounting principles (“GAAP”): gain or loss on foreign currency transactions, stock-based compensation expenses, and valuation allowance adjustments.  Management believes that “Adjusted Net Income” is useful to investors in gauging the outcome of the key drivers of the business performance:  the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control.  

 

Management has also excluded gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board’s Accounting Standards Codification (ASC) 718.  Valuation allowance adjustments can occur from time to time based on forecasted changes in operating results until all net operating loss carryforwards are fully utilized.  In calculating Adjusted Net Income, STAAR excludes these expenses because they are non-cash expenses and because of the considerable judgment involved in calculating their values.  In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.

The Company also uses Constant Currency as a Non-GAAP financial measure to exclude the effects of currency fluctuations on net sales. The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company’s results when reported in U.S. dollars. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the "constant currency" rate to sales or expenses in the current period as well. Because changes in currency are outside of the control of the Company and its managers, management finds this non-GAAP measure useful in determining the long-term progress of its initiatives and determining whether its managers are achieving their performance goals. The Company believes that the non-GAAP constant-currency sales results measures provided in this press release are similarly useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in relative currency values. The table below shows sales results calculated in accordance with GAAP, the effect of currency, and the resulting non-GAAP measure expressed in constant currency.  

3

 

 

 

About STAAR Surgical

 

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Safe Harbor

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2022 or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to its impact on sales, operations or clinical trials globally), product safety or effectiveness, the status of our pipeline of ICL products with regulators, including our EVO family of lenses in the U.S., and any statements of assumptions underlying any of the foregoing, including those relating to our product pipeline and market expansion activities. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to the COVID-19 pandemic and related public health measures, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of the COVID-19 pandemic on markets; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval, or to take enforcement action; international trade disputes; and the willingness of surgeons and patients to adopt a new or improved product and procedure. The EVO version of our ICL lens is not yet approved for sale in the United States.

 

 

CONTACT:Investors

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

 

Media

Jen Jones

Gold PR | Social Media

(310) 918-4313

jjones@goldpr.com

 

4

 

 

 

 

Consolidated Balance Sheets

(in 000's)

Unaudited

 

 

 

December 31,

2021

 

 

January 1,

2021

 

ASSETS

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

199,706

 

 

$

152,453

 

Accounts receivable trade, net

 

 

43,531

 

 

 

35,229

 

Inventories, net

 

 

17,274

 

 

 

18,111

 

Prepayments, deposits, and other current assets

 

 

10,900

 

 

 

10,625

 

Total current assets

 

 

271,411

 

 

 

216,418

 

Property, plant, and equipment, net

 

 

35,912

 

 

 

24,030

 

Finance lease right-of-use assets, net

 

 

506

 

 

 

596

 

Operating lease right-of-use assets, net

 

 

31,310

 

 

 

8,764

 

Intangible assets, net

 

 

218

 

 

 

270

 

Goodwill

 

 

1,786

 

 

 

1,786

 

Deferred income taxes

 

 

3,813

 

 

 

4,944

 

Other assets

 

 

822

 

 

 

608

 

Total assets

 

$

345,778

 

 

$

257,416

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Line of credit

 

$

-

 

 

$

1,379

 

Accounts payable

 

 

8,699

 

 

 

7,474

 

Obligations under finance leases

 

 

127

 

 

 

360

 

Obligations under operating leases

 

 

3,283

 

 

 

2,485

 

Allowance for sales returns

 

 

4,816

 

 

 

4,532

 

Other current liabilities

 

 

31,877

 

 

 

25,006

 

Total current liabilities

 

 

48,802

 

 

 

41,236

 

Obligations under finance leases

 

 

382

 

 

 

38

 

Obligations under operating leases

 

 

28,269

 

 

 

6,537

 

Deferred income taxes

 

 

811

 

 

 

222

 

Asset retirement obligations

 

 

198

 

 

 

221

 

Pension liability

 

 

8,758

 

 

 

11,940

 

Total liabilities

 

 

87,220

 

 

 

60,194

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

477

 

 

 

464

 

Additional paid-in capital

 

 

373,519

 

 

 

338,194

 

Accumulated other comprehensive loss

 

 

(4,048

)

 

 

(5,545

)

Accumulated deficit

 

 

(111,390

)

 

 

(135,891

)

Total stockholders' equity

 

 

258,558

 

 

 

197,222

 

Total liabilities and stockholders' equity

 

$

345,778

 

 

$

257,416

 

 

 

 

5

 

 

 

 

Consolidated Statements of Income

(In 000's except for per share data)

Unaudited

 

 

 

Three Months Ended

 

 

Twelve Months Ended

 

 

 

% of

 

December 31,

2021

 

 

% of

 

January 1,

2021

 

 

Fav (Unfav)

 

 

% of

 

December 31,

2021

 

 

% of

 

January 1,

2021

 

 

Fav (Unfav)

 

 

 

Sales

 

 

 

Sales

 

 

 

Amount

 

 

%

 

 

Sales

 

 

 

Sales

 

 

 

Amount

 

 

%

 

Net sales

 

 

100.0

%

$

59,001

 

 

 

100.0

%

$

45,998

 

 

$

13,003

 

 

 

28.3

%

 

 

100.0

%

$

230,472

 

 

 

100.0

%

$

163,460

 

 

$

67,012

 

 

 

41.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

 

23.7

%

 

14,010

 

 

 

25.4

%

 

11,697

 

 

 

(2,313

)

 

 

-19.8

%

 

 

22.5

%

 

51,835

 

 

 

27.6

%

 

45,098

 

 

 

(6,737

)

 

 

-14.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

76.3

%

 

44,991

 

 

 

74.6

%

 

34,301

 

 

 

10,690

 

 

 

31.2

%

 

 

77.5

%

 

178,637

 

 

 

72.4

%

 

118,362

 

 

 

60,275

 

 

 

50.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

19.5

%

 

11,471

 

 

 

20.7

%

 

9,505

 

 

 

(1,966

)

 

 

-20.7

%

 

 

19.1

%

 

44,142

 

 

 

20.7

%

 

33,911

 

 

 

(10,231

)

 

 

-30.2

%

Selling and marketing

 

 

28.9

%

 

17,065

 

 

 

25.6

%

 

11,761

 

 

 

(5,304

)

 

 

-45.1

%

 

 

29.2

%

 

67,294

 

 

 

28.0

%

 

45,764

 

 

 

(21,530

)

 

 

-47.0

%

Research and development

 

 

15.4

%

 

9,072

 

 

 

19.5

%

 

8,958

 

 

 

(114

)

 

 

-1.3

%

 

 

14.7

%

 

33,862

 

 

 

19.6

%

 

31,918

 

 

 

(1,944

)

 

 

-6.1

%

Total selling, general, and administrative expenses

 

 

63.8

%

 

37,608

 

 

 

65.8

%

 

30,224

 

 

 

(7,384

)

 

 

-24.4

%

 

 

63.0

%

 

145,298

 

 

 

68.3

%

 

111,593

 

 

 

(33,705

)

 

 

-30.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

 

12.5

%

 

7,383

 

 

 

8.8

%

 

4,077

 

 

 

3,306

 

 

 

81.1

%

 

 

14.5

%

 

33,339

 

 

 

4.1

%

 

6,769

 

 

 

26,570

 

 

 

392.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

0.0

%

 

(3

)

 

 

0.0

%

 

1

 

 

 

(4

)

 

 

-400.0

%

 

 

0.0

%

 

(38

)

 

 

0.1

%

 

238

 

 

 

(276

)

 

 

-116.0

%

Gain (loss) on foreign currency transactions

 

 

-1.6

%

 

(924

)

 

 

1.0

%

 

476

 

 

 

(1,400

)

 

 

-294.1

%

 

 

-1.3

%

 

(2,964

)

 

 

0.5

%

 

864

 

 

 

(3,828

)

 

 

-443.1

%

Royalty income

 

 

0.9

%

 

519

 

 

 

0.5

%

 

201

 

 

 

318

 

 

 

158.2

%

 

 

0.4

%

 

1,015

 

 

 

0.3

%

 

440

 

 

 

575

 

 

 

130.7

%

Other income (expense), net

 

 

0.0

%

 

(1

)

 

 

0.1

%

 

39

 

 

 

(40

)

 

 

-102.6

%

 

 

0.0

%

 

(48

)

 

 

0.0

%

 

(44

)

 

 

(4

)

 

 

-9.1

%

Total other income (expense), net

 

 

-0.7

%

 

(409

)

 

 

1.6

%

 

717

 

 

 

(1,126

)

 

 

-157.0

%

 

 

-0.9

%

 

(2,035

)

 

 

0.9

%

 

1,498

 

 

 

(3,533

)

 

 

-235.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before provision for income taxes

 

 

11.8

%

 

6,974

 

 

 

10.4

%

 

4,794

 

 

 

2,180

 

 

 

45.5

%

 

 

13.6

%

 

31,304

 

 

 

5.0

%

 

8,267

 

 

 

23,037

 

 

 

278.7

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

 

3.5

%

 

2,052

 

 

 

3.2

%

 

1,467

 

 

 

(585

)

 

 

-39.9

%

 

 

3.0

%

 

6,803

 

 

 

1.4

%

 

2,354

 

 

 

(4,449

)

 

 

-189.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

8.3

%

$

4,922

 

 

 

7.2

%

$

3,327

 

 

$

1,595

 

 

 

47.9

%

 

 

10.6

%

$

24,501

 

 

 

3.6

%

$

5,913

 

 

$

18,588

 

 

 

314.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share - basic

 

 

 

 

$

0.10

 

 

 

 

 

$

0.07

 

 

 

 

 

 

 

 

 

 

 

 

 

$

0.52

 

 

 

 

 

$

0.13

 

 

 

 

 

 

 

 

 

Net income per share - diluted

 

 

 

 

$

0.10

 

 

 

 

 

$

0.07

 

 

 

 

 

 

 

 

 

 

 

 

 

$

0.50

 

 

 

 

 

$

0.12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding - basic

 

 

 

 

 

47,652

 

 

 

 

 

 

46,264

 

 

 

 

 

 

 

 

 

 

 

 

 

 

47,210

 

 

 

 

 

 

45,605

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding - diluted

 

 

 

 

 

49,478

 

 

 

 

 

 

48,808

 

 

 

 

 

 

 

 

 

 

 

 

 

 

49,456

 

 

 

 

 

 

47,953

 

 

 

 

 

 

 

 

 

 

 

6

 

 

 

 

Consolidated Statements of Cash Flows

(in 000's)

Unaudited

 

 

 

Three Months Ended

 

 

Twelve Months Ended

 

 

 

December 31,

2021

 

 

January 1,

2021

 

 

December 31,

2021

 

 

January 1,

2021

 

 

 

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

4,922

 

 

$

3,327

 

 

$

24,501

 

 

$

5,913

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation of property and equipment

 

 

937

 

 

 

784

 

 

 

3,608

 

 

 

3,060

 

Amortization of long-lived intangibles

 

 

8

 

 

 

9

 

 

 

34

 

 

 

35

 

Deferred income taxes

 

 

650

 

 

 

366

 

 

 

1,495

 

 

 

(849

)

Change in net pension liability

 

 

46

 

 

 

134

 

 

 

137

 

 

 

656

 

Stock-based compensation expense

 

 

3,620

 

 

 

3,181

 

 

 

14,605

 

 

 

12,146

 

Loss on disposal of property and equipment

 

 

-

 

 

 

210

 

 

 

2

 

 

 

213

 

Provision for sales returns and bad debts

 

 

(751

)

 

 

20

 

 

 

318

 

 

 

835

 

Inventory provision

 

 

557

 

 

 

511

 

 

 

1,654

 

 

 

1,706

 

Changes in working capital:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(1,796

)

 

 

7,001

 

 

 

(8,868

)

 

 

(3,974

)

Inventories

 

 

(1,235

)

 

 

(37

)

 

 

66

 

 

 

(1,390

)

Prepayments, deposits and other current assets

 

 

(1,999

)

 

 

(3,117

)

 

 

(711

)

 

 

(3,753

)

Accounts payable

 

 

148

 

 

 

(542

)

 

 

108

 

 

 

(1,199

)

Other current liabilities

 

 

3,391

 

 

 

7,703

 

 

 

7,013

 

 

 

7,552

 

Net cash provided by operating activities

 

 

8,498

 

 

 

19,550

 

 

 

43,962

 

 

 

20,951

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition of property and equipment

 

 

(4,689

)

 

 

(2,145

)

 

 

(13,645

)

 

 

(8,404

)

Net cash used in investing activities

 

 

(4,689

)

 

 

(2,145

)

 

 

(13,645

)

 

 

(8,404

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repayment on line of credit

 

 

(1,297

)

 

 

(4

)

 

 

(1,297

)

 

 

(515

)

Repayment of finance lease obligations

 

 

(34

)

 

 

(106

)

 

 

(348

)

 

 

(561

)

Proceeds from vested restricted stock and exercise of stock options

 

 

1,115

 

 

 

6,660

 

 

 

19,438

 

 

 

20,647

 

Net cash provided by (used in) financing activities

 

 

(216

)

 

 

6,550

 

 

 

17,793

 

 

 

19,571

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

 

(133

)

 

 

160

 

 

 

(857

)

 

 

367

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Increase in cash and cash equivalents

 

 

3,460

 

 

 

24,115

 

 

 

47,253

 

 

 

32,485

 

Cash and cash equivalents, at beginning of the period

 

 

196,246

 

 

 

128,338

 

 

 

152,453

 

 

 

119,968

 

Cash and cash equivalents, at end of the period

 

$

199,706

 

 

$

152,453

 

 

$

199,706

 

 

$

152,453

 

 

7

 

 

 

 

Reconciliation of Non-GAAP Financial Measure

Adjusted Net Income and Net Income Per Share

(in 000's)

Unaudited

 

 

 

Three Months Ended

 

 

Twelve Months Ended

 

 

 

December 31,

2021

 

January 1,

2021

 

 

December 31,

2021

 

January 1,

2021

 

 

 

 

 

 

 

 

Net income (as reported)

 

$

4,922

 

$

3,327

 

 

$

24,501

 

$

5,913

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Foreign currency impact

 

 

924

 

 

(476

)

 

 

2,964

 

 

(864

)

  Stock-based compensation expense

 

 

3,620

 

 

3,181

 

 

 

14,605

 

 

12,146

 

  Valuation allowance adjustment

 

 

-

 

 

720

 

 

 

845

 

 

(495

)

Net income (adjusted)

 

$

9,466

 

$

6,752

 

 

$

42,915

 

$

16,700

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share, basic (as reported)

 

$

0.10

 

$

0.07

 

 

$

0.52

 

$

0.13

 

Foreign currency impact

 

 

0.02

 

 

(0.01

)

 

 

0.06

 

 

(0.02

)

Stock-based compensation expense

 

 

0.08

 

 

0.07

 

 

 

0.31

 

 

0.27

 

Valuation allowance adjustment

 

 

-

 

 

0.02

 

 

 

0.02

 

 

(0.01

)

Net income per share, basic (adjusted)

 

$

0.20

 

$

0.15

 

 

$

0.91

 

$

0.37

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share, diluted (as reported)

 

$

0.10

 

$

0.07

 

 

$

0.50

 

$

0.12

 

Foreign currency impact

 

 

0.02

 

 

(0.01

)

 

 

0.06

 

 

(0.02

)

Stock-based compensation expense

 

 

0.07

 

 

0.07

 

 

 

0.29

 

 

0.25

 

Valuation allowance adjustment

 

 

-

 

 

0.01

 

 

 

0.02

 

 

-

 

Net income per share, diluted (adjusted)

 

$

0.19

 

$

0.14

 

 

$

0.87

 

$

0.35

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding - Basic

 

 

47,652

 

 

46,264

 

 

 

47,210

 

 

45,605

 

Weighted average shares outstanding - Diluted

 

 

49,478

 

 

48,808

 

 

 

49,456

 

 

47,953

 

 

Note:  Net income per share (adjusted), basic and diluted, may not add due to rounding

8

 

 

 

STAAR Surgical Company

Reconciliation of Non-GAAP Financial Measure

Constant Currency Sales

(in 000's)

Unaudited

 

 

Three Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

2021

 

Effect of

 

Constant

 

 

January 1,

2021

 

 

As Reported

 

 

Constant Currency

 

Sales

 

Currency

 

Currency

 

 

 

 

$ Change

 

% Change

 

 

$ Change

 

% Change

 

ICL

$

53,016

 

$

846

 

$

53,862

 

 

$

39,846

 

 

$

13,170

 

 

33.1

%

 

$

14,016

 

 

35.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cataract IOL

 

3,195

 

 

201

 

 

3,396

 

 

 

3,694

 

 

 

(499

)

 

-13.5

%

 

 

(298

)

 

-8.1

%

Other

 

2,790

 

 

173

 

 

2,963

 

 

 

2,458

 

 

 

332

 

 

13.5

%

 

 

505

 

 

20.5

%

Other Products

 

5,985

 

 

374

 

 

6,359

 

 

 

6,152

 

 

 

(167

)

 

-2.7

%

 

 

207

 

 

3.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Sales

$

59,001

 

$

1,220

 

$

60,221

 

 

$

45,998

 

 

$

13,003

 

 

28.3

%

 

$

14,223

 

 

30.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Twelve Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

2021

 

Effect of

 

Constant

 

 

January 1,

2021

 

 

As Reported

 

 

Constant Currency

 

Sales

 

Currency

 

Currency

 

 

 

 

$ Change

 

% Change

 

 

$ Change

 

% Change

 

ICL

$

212,905

 

$

(759

)

$

212,146

 

 

$

141,407

 

 

$

71,498

 

 

50.6

%

 

$

70,739

 

 

50.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cataract IOL

 

12,519

 

 

19

 

 

12,538

 

 

 

13,574

 

 

 

(1,055

)

 

-7.8

%

 

 

(1,036

)

 

-7.6

%

Other

 

5,048

 

 

243

 

 

5,291

 

 

 

8,479

 

 

 

(3,431

)

 

-40.5

%

 

 

(3,188

)

 

-37.6

%

Other Products

 

17,567

 

 

262

 

 

17,829

 

 

 

22,053

 

 

 

(4,486

)

 

-20.3

%

 

 

(4,224

)

 

-19.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Sales

$

230,472

 

$

(497

)

$

229,975

 

 

$

163,460

 

 

$

67,012

 

 

41.0

%

 

$

66,515

 

 

40.7

%

 

 

9

 

 GRAPHIC 3 gplszq1uoal5000001.jpg GRAPHIC begin 644 gplszq1uoal5000001.jpg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staa-20220223.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 staa-20220223_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol(s) Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 6 staa-20220223_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document And Entity Information
Feb. 23, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 23, 2022
Entity Registrant Name STAAR Surgical Co
Entity Central Index Key 0000718937
Entity Emerging Growth Company false
Entity File Number 0-11634
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 95-3797439
Entity Address, Address Line One 25651 Atlantic Ocean Drive
Entity Address, City or Town Lake Forest
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92630
City Area Code 626
Local Phone Number 303-7902
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common
Trading Symbol(s) STAA
Name of each exchange on which registered NASDAQ
XML 8 staa-8k_20220223_htm.xml IDEA: XBRL DOCUMENT 0000718937 2022-02-23 2022-02-23 false 0000718937 8-K 2022-02-23 STAAR Surgical Co DE 0-11634 95-3797439 25651 Atlantic Ocean Drive Lake Forest CA 92630 626 303-7902 false false false false Common STAA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports staa-8k_20220223.htm staa-20220223.xsd staa-20220223_lab.xml staa-20220223_pre.xml staa-ex991_6.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "staa-8k_20220223.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "staa-8k_20220223.htm" ] }, "labelLink": { "local": [ "staa-20220223_lab.xml" ] }, "presentationLink": { "local": [ "staa-20220223_pre.xml" ] }, "schema": { "local": [ "staa-20220223.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "staa", "nsuri": "http://www.staar.com/20220223", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "staa-8k_20220223.htm", "contextRef": "C_0000718937_20220223_20220223", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "staa-8k_20220223.htm", "contextRef": "C_0000718937_20220223_20220223", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol(s)" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.staar.com/20220223/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-22-006349-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-006349-xbrl.zip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